BR0208987A - Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv - Google Patents

Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv

Info

Publication number
BR0208987A
BR0208987A BR0208987-4A BR0208987A BR0208987A BR 0208987 A BR0208987 A BR 0208987A BR 0208987 A BR0208987 A BR 0208987A BR 0208987 A BR0208987 A BR 0208987A
Authority
BR
Brazil
Prior art keywords
transcriptase inhibitors
tricyclic compounds
hiv
spare
compounds useful
Prior art date
Application number
BR0208987-4A
Other languages
English (en)
Inventor
Barry L Johnson
James D Rodgers
Qiyan Lin
Anurag S Srivastava
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0208987A publication Critical patent/BR0208987A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSTOS TRICìCLICOS úTEIS COMO INIBIDORES DE TRANSCRIPTASE REVERSA DE HIV". A presente invenção refere-se a compostos tricíclicos da fórmula (I) ou suas formas estereoisoméricas, misturas estereoisoméricas, ou sais de uso farmacêutico, que são úteis como inibidores de transcriptase reversa de HIV, e composições farmacêuticas e kits diagnósticos que compreendem os mesmos, e métodos para usar os mesmos para tratar infecção viral, ou como um padrão ou reagente de ensaio.
BR0208987-4A 2001-04-19 2002-04-17 Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv BR0208987A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28481801P 2001-04-19 2001-04-19
PCT/US2002/012208 WO2002085365A1 (en) 2001-04-19 2002-04-17 Tricyclic compounds useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BR0208987A true BR0208987A (pt) 2004-04-27

Family

ID=23091633

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208987-4A BR0208987A (pt) 2001-04-19 2002-04-17 Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv

Country Status (10)

Country Link
US (1) US6825210B2 (pt)
EP (1) EP1379248A1 (pt)
JP (1) JP2004532224A (pt)
CN (1) CN1649591A (pt)
AR (1) AR033702A1 (pt)
BR (1) BR0208987A (pt)
CA (1) CA2444570A1 (pt)
HU (1) HUP0303818A2 (pt)
MX (1) MXPA03009482A (pt)
WO (1) WO2002085365A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637890D1 (de) 1995-06-07 2009-05-14 Progenics Pharm Inc Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
WO2005027855A2 (en) * 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
ES2438019T3 (es) * 2005-07-22 2014-01-15 Cytodyn, Inc. Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
KR20100102087A (ko) * 2007-07-13 2010-09-20 인터몰레큘러 인코퍼레이티드 로우-ｋ 유전체 재료의 표면 개질

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262294D1 (en) 1981-05-13 1985-03-28 Ici Plc Pharmaceutical compositions containing spiro succinimide derivatives
US5171745A (en) 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
HUT71132A (en) 1992-03-27 1995-11-28 Schering Corp Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2145407C (en) 1992-09-28 2009-09-22 Louis A. Carpino New reagents for peptide couplings
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
WO1995012583A1 (en) 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
WO1996031469A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5874430A (en) 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
AU4719799A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6593337B1 (en) 1999-10-19 2003-07-15 Bristol-Myers Squibb Pharma Company Tricyclic compounds useful as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2004532224A (ja) 2004-10-21
AR033702A1 (es) 2004-01-07
MXPA03009482A (es) 2004-02-12
US20020177603A1 (en) 2002-11-28
WO2002085365A1 (en) 2002-10-31
US6825210B2 (en) 2004-11-30
CN1649591A (zh) 2005-08-03
HUP0303818A2 (hu) 2004-03-01
CA2444570A1 (en) 2002-10-31
EP1379248A1 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
BR0015056A (pt) Composto, uso de um composto, composição farmacêutica, método de tratamento de infecções por hiv e kit farmacêutico
BR9808513A (pt) Composto, composição farmacêutica, método para tratamento de infecções por hiv e kit farmacêutico.
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BR0208987A (pt) Composto tricìclicos úteis como inibidores de transcriptase reserva de hiv
BRPI0418639A (pt) inibidores de dipeptidil peptidase
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
EA200970052A1 (ru) 2-(замещенные амино)бензотиазолсульфонамидные ингибиторы вич-протеазы
BR0215016A (pt) Piridoquinoxalinas antivirìcas
TW200710091A (en) (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
NO20065582L (no) (1,lOB-dihydro-2-(amtnokarbonyl-fenyl)-SH-pyrazolo[1,5-C][1,3]benzoksazin-5-yl)fenylmetanonderivater som HIV-virusreplikasjonsinhibitorer
BR0112606A (pt) Compostos tricìclicos 2-piridona úteis como inibidores de transcriptase inversa de hiv
BRPI0414199A (pt) inibidores de entrada do vìrus hiv
WO2004002410A3 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
BR0208967A (pt) Monoazocorantes fibrorreativos
BR9814933A (pt) Composto, composicao farmaceutica e metodo de tratamento de infeccao por hiv.
BR0007854A (pt) Compostos sulfonamidas bis-aminoácidos inibidores de protease de hiv, composição farmacêutica e método de tratamento de infecções por hiv
BR9712755A (pt) Composto, composição farmacêutica, método para o tratamento de infecção por hiv e kit farmacêutico útil para o tratamento de infecção por hiv
BR9712910A (pt) ra o tratamento de infecção por hiv
GT200200140A (es) Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico
WO2000073284A3 (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]